Kewaunee Scientific Corporation KEQU
34.02
(0.26)
(0.76%)
as of 25 Sep
- Market cap
- $99.3M
- P/E
- 11.9×
Follow KEQU
Growth Flags
show if company had growth for consecutive years
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
10.20 | 10.39 | 11.05 | 12.49 |
P/S ratio |
0.42 | 0.40 | 0.38 | 0.37 | |
P/FCF ratio |
23.40 | 6.04 | 7.21 | 9.46 | |
P/Operating CF |
(28.10) | 9.89 | 19.41 | 52.06 | |
P/B ratio |
1.67 | 1.59 | 1.38 | 1.33 | |
Price to Tangible BV |
2.84 | 2.66 | 2.21 | 2.11 | |
EV/Sales |
0.59 | 0.53 | 0.50 | 0.50 | |
EV/EBITDA |
6.38 | 5.66 | 5.98 | 6.29 | |
EV/Operating CF |
19.39 | 6.77 | 7.56 | 9.30 | |
EV/FCF |
32.82 | 8.02 | 9.59 | 12.66 | |
Quick Ratio |
1.59 | 1.32 | 1.46 | 1.45 | |
Current Ratio |
2.48 | 2.12 | 2.18 | 2.20 | |
Net Debt/EBITDA |
8.34 | 8.38 | 5.13 | 7.26 | |
Debt/Assets |
32.74% | 27.31% | 26.14% | 25.69% | |
Debt/Equity |
0.86 | 0.66 | 0.61 | 0.58 | |
Asset Turnover |
1.76 | 1.58 | 1.51 | 1.50 | |
Operating CF/Net income |
(1.74) | 16.83 | 1.61 | 1.16 | |
Capex/Depreciation |
(0.94) | (0.35) | (0.58) | (0.47) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.16 | 0.17 | 0.16 | 0.16 | |
Share Based Compensation of Revenue |
0.80% | 0.78% | 0.70% | 2.86% | |
Graham Net Nets |
(0.03) | 0.00 | 0.04 | 0.05 | |
Graham Number |
48.05 | 46.94 | 44.97 | 41.54 | |
Earnings Yield |
9.80% | 9.63% | 9.05% | 8.01% | |
Free Cash Flow Yield |
4.27% | 16.54% | 13.87% | 10.58% | |
Revenue per Share |
24.46 | 24.21 | 24.94 | 23.03 | |
Operating CF per Share |
(1.49) | 4.06 | 1.91 | 0.69 | |
Capex per Share |
(0.55) | (0.23) | (0.32) | (0.27) | |
Free Cash Flow per Share |
(2.04) | 3.83 | 1.58 | 0.42 | |
Cash per Share |
4.77 | 3.61 | 4.06 | 3.56 | |
Shareholders Equity per Share |
25.02 | 25.31 | 26.83 | 26.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
25.02 | 25.31 | 26.83 | 26.81 | |
Free Cash Flow |
(5.83) | 10.98 | 4.53 | 1.20 | |
Working Capital |
67.83 | 54.79 | 57.05 | 56.72 | |
Capital Expenditures |
(1.57) | (0.67) | (0.93) | (0.77) | |
Net Current Asset Value |
(3.72) | 0.15 | 3.90 | 5.37 | |
EV/EBIT |
8.55 | 7.65 | 8.43 | 9.15 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
3.49% | 1.00% | 4.75% | 2.57% | |
Price to Operating Income |
6.09 | 5.76 | 6.34 | 6.83 | |
| Other line items | |||||
Average Receivables |
50.45 | 55.78 | 60.56 | 57.55 | |
Average Payables |
22.06 | 24.09 | 24.74 | 23.94 | |
Average Inventory |
27.08 | 32.23 | 31.69 | 32.35 | |
Average Assets |
161.78 | 182.55 | 186.48 | 184.64 | |
Average Common Equity |
66.19 | 67.32 | 71.53 | 73.04 |
Columns are period end dates